Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/20/2026 | Buy → Neutral | Goldman | ||
| 10/15/2025 | Neutral → Underperform | BofA Securities | ||
| 9/2/2025 | Neutral → Sell | UBS | ||
| 12/2/2024 | Underperform → Neutral | BofA Securities | ||
| 11/6/2024 | $25.60 | Buy | Berenberg | |
| 3/6/2024 | $133.00 | Equal Weight | Barclays | |
| 1/8/2024 | Equal-Weight → Underweight | Morgan Stanley | ||
| 11/24/2023 | Reduce → Hold | HSBC Securities |
Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).For more than two dec
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investorsThe collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territoryAlebund holds a substantial non-dilutive equit
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc ("R1"), a clinical-stage biopharmaceutical company focused on the development of first-in-class thera
3 - Fresenius Medical Care AG (0001333141) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
SCHEDULE 13G/A - DAVITA INC. (0000927066) (Subject)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
Goldman downgraded Fresenius Medical from Buy to Neutral
BofA Securities downgraded Fresenius Medical from Neutral to Underperform
UBS downgraded Fresenius Medical from Neutral to Sell
SC 13G - Fresenius Medical Care AG (0001333141) (Subject)
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)
Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical OfficerAs part of a planned transition Franklin W. Maddux will retire by year endBAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer. Mr. Hugh-Jones will succeed Franklin (F
Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care EnablementAs part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year endBAD HOMBURG, Germany, Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, has appointed Joseph E. (Joe) Turk (57) as a member of the Management Board, effective January 1, 2026. Mr. Turk will serve as Chief Executive Officer of the global operating segment Care Enablement.
Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set during the merger of Cricket Health, IWH, and Fresenius Health Partners when it was completed in August 2022Tommy P. O'Connor appointed CEO of Interwell Health and Operating Segment leader of Value-Based Care to enhance benefits of the vertical integration and accelerate value creation in line with the FME Reignite strategyBAD HOMBURG, Germany, Sept. 18, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, to
Strong organic revenue growth1 in 2025 of 8% driven by all operating segmentsDriven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%Reported operating income grew by 31%, reported net income3 by 82%Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback programDividend of EUR 1.49 (+3%) planned to be proposedFY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwindsBAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains.
DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion
DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Monday, February 2, 2026Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen